Glaxo Is ‘Happy’ With Human Genome Relationship, Viiv Venture
GlaxoSmithKline Plc (GSK) is “very happy” with its current relationship with Human Genome Sciences Inc. (HGSI), Chief Financial Officer Simon Dingemans said.
“I see the rumors from time to time, it makes no difference to how we operate with them,” Dingemans said in an interview in San Francisco yesterday, speaking about speculation that London-based Glaxo may make a bid for Human Genome.
Dingemans said the U.K. drugmaker also is “very happy with the performance” of its Viiv Healthcare Ltd. venture with Pfizer Inc. (PFE), which specializes in HIV treatments.
“It’s generating a lot of value for us and for Pfizer,” he said. “We are very happy with the structure that’s delivering that value.” Glaxo remains “open-minded” about options for Viiv in the future “but at the moment we are perfectly fine” with the current structure, Dingemans added.
Glaxo isn’t interested in the prescription medicines business of Abbott Laboratories (ABT), Dingemans also said.
To contact the editor responsible for this story: Albertina Torsoli at atorsoli@bloomberg.net
Rate this Page
Bloomberg moderates all comments. Comments that are abusive or off-topic will not be posted to the site. Excessively long comments may be moderated as well. Bloomberg cannot facilitate requests to remove comments or explain individual moderation decisions.